All In Biotech

Drug Trial Radar · NCT05933265

Study of LP-184 in Patients With Advanced Solid Tumors

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

64

Actual

Start

Jun 9, 2023

Primary completion

Jul 28, 2026

Study completion Jul 28, 2026

Sponsor

Lead sponsor
Lantern Pharma Inc.Industry
Sponsor type
Industry
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • GBM
  • TNBC - Triple-Negative Breast Cancer
  • NSCLC
  • Pancreatic Adenocarcinoma
  • DDR Gene Mutation

Interventions

  • LP-184Drug

    LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.

  • OlaparibDrug

    A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.

  • Nivolumab & IpilimumabDrug

    Nivolumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the PD-1 receptor on the surface of T cells, Nivolumab restores immune cells' ability to recognize and attack cancer cells. Ipilimumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the CTLA4 protein on the surface of T cells, Ipilimumab activates T-cells and allows T-cells to attack cancer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0Time frame: 12 months
  2. To determine the MTD of LP-184 based on all available safety (graded by CTCAE v5.0) and PK data.Time frame: 12 months
  3. To determine the RP2D of LP-184 based on all available safety (graded by CTCAE v5.0), PK, PD and efficacy dataTime frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Norton Healthcare, Inc.

    Louisville, Kentucky

  • John Hopkins - The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UT Health Science Center San Antonio

    San Antonio, Texas

  • START Mountain Region

    West Valley City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.